keyword
MENU ▼
Read by QxMD icon Read
search

vedolizumab crohn's

keyword
https://www.readbyqxmd.com/read/29140943/antibodies-toward-vedolizumab-appear-from-the-first-infusion-onward-and-disappear-over-time
#1
Sumin Bian, Erwin Dreesen, Ho Tsun Tang, Griet Compernolle, Miet Peeters, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
BACKGROUND: Vedolizumab (VDZ) has been approved for the treatment of patients with moderate-to-severe Crohn's disease and ulcerative colitis. The GEMINI trials reported a low prevalence of anti-VDZ antibodies (AVA). However, the AVA assays used in GEMINI were drug sensitive, resulting in a possible underestimation of the rate of AVA formation. This study aimed to monitor immunogenicity of VDZ in a real-life cohort using a drug-resistant AVA assay. METHODS: Using a combination of VDZ/AVA complex precipitation and acid dissociation, a drug-resistant assay for AVA detection in the presence of high VDZ concentrations has been developed and analytically validated...
December 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29139091/pharmacological-approach-to-the-management-of-crohn-s-disease-patients-with-perianal-disease
#2
REVIEW
Fernando Bermejo, Iván Guerra, Alicia Algaba, Antonio López-Sanromán
Perianal localization of Crohn's disease involves significant morbidity, affects quality of life and results in an increased use of healthcare resources. Medical and surgical therapies contribute to its management. The objective of this review is to address the current understanding in the management of perianal Crohn's disease, with the main focus in reviewing pharmacological therapies, including stem cells. In complex fistulas, once local sepsis has been controlled by surgical drainage and/or antibiotics, anti-TNF drugs (infliximab, adalimumab) are the first-line therapy, with or without associated immunomodulators...
November 14, 2017: Drugs
https://www.readbyqxmd.com/read/29115855/an-indirect-comparison-of-ustekinumab-and-vedolizumab-in-the-therapy-of-tnf-failure-crohn-s-disease-patients
#3
Paweł Kawalec, Paweł Moćko
AIM: An indirect comparison of ustekinumab versus vedolizumab in patients with active moderate-to-severe Crohn's disease who were nonresponsive or intolerant to previous TNF-antagonist therapy. METHODS: A systematic review was performed in Medline via PubMed, Embase, Cochrane Library, until 30 April 2017. Inclusion criteria were: randomized controlled trials, patients treated for Crohn's disease, ustekinumab or vedolizumab therapy. Included trials were critically appraised and afterward indirect comparison by Bucher was conducted; the manuscript was prepared in accordance to the PRISMA requirements...
November 8, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29077833/vedolizumab-in-ibd-lessons-from-real-world-experience-a-systematic-review-and-pooled-analysis
#4
Tal Engel, Bella Ungar, Diana E Yung, Shomron Ben-Horin, Rami Eliakim, Uri Kopylov
Background: Vedolizumab (VDZ) is an anti-integrin monoclonal antibody effective in ulcerative colitis (UC) and Crohn's disease (CD). Several real-world experience (RWE) studies with VDZ were published to date. The aim of this systematic review was to summarize the available real-life experience with VDZ. Methods: We performed a systematic review of the available RWE studies of VDZ in CD and UC. We performed a pooled analysis of the available efficacy and safety data for induction and maintenance treatment in adult cohorts...
October 25, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28974896/access-to-biologicals-in-crohn-s-disease-in-ten-european-countries
#5
Márta Péntek, Peter L Lakatos, Talitha Oorsprong, László Gulácsi, Milena Pavlova, Wim Groot, Fanni Rencz, Valentin Brodszky, Petra Baji, Crohn's Disease Research Group
AIM: To analyze access (availability, affordability and acceptability) to biologicals for Crohn's disease (CD) in ten European countries and to explore the associations between these dimensions, the uptake of biologicals and economic development. METHODS: A questionnaire-based survey combined with desk research was carried out in May 2016. Gastroenterologists from the Czech Republic, France, Germany, Hungary, Latvia, Poland, Romania, Slovakia, Spain and Sweden were invited to participate and provide data on the availability of biologicals/biosimilars, reimbursement criteria, clinical practice and prices, and use of biologicals...
September 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28973005/a-systematic-review-of-cost-effectiveness-studies-comparing-conventional-biological-and-surgical-interventions-for-inflammatory-bowel-disease
#6
REVIEW
Nadia Pillai, Mark Dusheiko, Bernard Burnand, Valérie Pittet
BACKGROUND: Inflammatory bowel disease (IBD) is a chronic disease placing a large health and economic burden on health systems worldwide. The treatment landscape is complex with multiple strategies to induce and maintain remission while avoiding long-term complications. The extent to which rising treatment costs, due to expensive biologic agents, are offset by improved outcomes and fewer hospitalisations and surgeries needs to be evaluated. This systematic review aimed to assess the cost-effectiveness of treatment strategies for IBD...
2017: PloS One
https://www.readbyqxmd.com/read/28961959/the-expanding-therapeutic-armamentarium-for-inflammatory-bowel-disease-how-to-choose-the-right-drug-s-for-our-patients
#7
Pieter Hindryckx, Niels Vande Casteele, Gregor Novak, Reena Khanna, Geert D'Haens, William J Sandborn, Silvio Danese, Vipul Jairath, Brian G Feagan
The therapeutic landscape for inflammatory bowel disease (IBD) is rapidly evolving. Two new biologic drugs, vedolizumab and ustekinumab, have recently entered the marketplace, the first biosimilars have been introduced, and several other agents are at an advanced stage of clinical development. In parallel, therapeutic goals have shifted from symptom control towards mucosal healing and prevention of bowel damage. In the coming years, gastroenterologists will be faced with unprecedented choices when selecting the best treatment for their patients with IBD...
August 25, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28953016/nodular-vasculitis-in-a-patient-with-crohn-s-disease-on-vedolizumab
#8
Delila Pouldar, Ashley Elsensohn, Francesca Ortenzio, Jessica Shiu, Michael McLeod, Sébastien de Feraudy
Erythema induratum (EI), or nodular vasculitis (NV), is a type of panniculitis that is often associated with vasculitis affecting various-sized veins, venules, and arteries in reaction to various causative factors. Historically, EI was highly linked to tuberculosis, but in 1946, Montgomery first proposed the term NV to describe cases of EI not associated with tuberculosis. Only 2 reports of NV associated with inflammatory bowel disease have been reported in the literature. The authors report a 60-year-old woman with Crohn's disease presenting with exacerbation of NV in the setting of vedolizumab therapy...
September 20, 2017: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/28858074/efficacy-of-combination-vedolizumab-and-ustekinumab-for-refractory-crohn-s-disease
#9
Kayci Huff-Hardy, Mai Bedair, Rebecca Vazquez, Ezra Burstein
No abstract text is available yet for this article.
August 29, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28839909/vedolizumab-early-experience-and-medium-term-outcomes-from-two-uk-tertiary-ibd-centres
#10
Mark A Samaan, Polychronis Pavlidis, Emma Johnston, Ben Warner, Jonathan Digby-Bell, Ioannis Koumoutsos, Steven Fong, Rimma Goldberg, Kamal Patel, Shraddha Gulati, Lucy Medcalf, Marlene Sastrillo, Cordella Brown-Clarke, Johanna Bidewell-Sullivan, Katrina Forsyth, Emma Lee, Anna Stanton, Julie Duncan, Guy Chung-Faye, Patrick Dubois, Nick Powell, Simon Anderson, Jeremy Sanderson, Bu'Hussain Hayee, Peter M Irving
OBJECTIVE: To gain an understanding of the efficacy of vedolizumab in a 'real-world' setting. DESIGN: Retrospective cohort study using prospectively maintained clinical records. SETTING: Two UK tertiary inflammatory bowel disease (IBD) centres. PATIENTS: Patients with IBD commenced on vedolizumab at Guy's & St Thomas' and King's College Hospitals during November 2014-November 2015. INTERVENTION: Vedolizumab, a monoclonal antibody to α-4 β-7 integrins that selectively inhibit leucocyte migration into the gut...
July 2017: Frontline Gastroenterology
https://www.readbyqxmd.com/read/28838418/ustekinumab-and-anti-interleukin-23-agents-in-crohn-s-disease
#11
REVIEW
Parakkal Deepak, William J Sandborn
This article reviews the available data regarding the efficacy of ustekinumab across published randomized clinical trials and open-label experience from tertiary medical centers, safety data, including in pregnancy, and its use in patients who have failed tumor necrosis factor (TNF) antagonists as well as patients who have not failed TNF antagonists. We have proposed an algorithm for positioning the use of ustekinumab among other agents (TNF antagonists, vedolizumab) in moderate-severe Crohn's disease. The article also enumerates drugs that are specific interleukin-23 blockers, including brazikumab (MEDI2070), risankizumab, LY3074828, tildrakizumab, and guselkumab, and the current status of their clinical trials...
September 2017: Gastroenterology Clinics of North America
https://www.readbyqxmd.com/read/28838417/use-of-anti-tumor-necrosis-factors-and-anti-integrins-in-the-treatment-of-crohn-s-disease
#12
REVIEW
Raina Shivashankar, Darrell S Pardi
In patients with Crohn's disease (CD), anti-tumor necrosis factor (TNF) therapy is efficacious for the induction and maintenance of clinical remission, mucosal healing, reducing rates of surgery and hospitalizations, and improving health-related quality of life. The decision between anti-TNFs and anti-integrins as first-line treatment in CD depends on disease severity, safety concerns, and prescription coverage. Given the existing data on long-term outcomes and safety, anti-TNFs are often preferred to anti-integrins...
September 2017: Gastroenterology Clinics of North America
https://www.readbyqxmd.com/read/28832222/natalizumab-in-the-treatment-of-crohn-s-disease-patients
#13
Cristiano Pagnini, Kristen O Arseneau, Fabio Cominelli
Amongst the available therapies for moderate to severe Crohn's disease (CD) patients who are refractory to conventional therapy, anti-TNF blockers are the most effective biological treatment option. However, many patients experience a primary or secondary non-response to anti-TNF therapy, creating the need for alternative biological drugs that target different mechanisms of action and inflammatory pathways. Natalizumab, the first non-anti-TNF biological drug to be approved for treatment of CD patients, is a recombinant humanized antibody that targets the α4-subunit of both α4β1 and α4β7 integrins, thus preventing activated leukocyte homing to the intestinal mucosa...
August 23, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28829369/systemic-chemokine-levels-with-gut-specific-vedolizumab-in-patients-with-inflammatory-bowel-disease-a-pilot-study
#14
Stephanie Zwicker, Ronaldo Lira-Junior, Charlotte Höög, Sven Almer, Elisabeth A Boström
Vedolizumab, a gut-specific biological treatment for inflammatory bowel disease (IBD), is an antibody that binds to the α₄β₇ integrin and blocks T-cell migration into intestinal mucosa. We aimed to investigate chemokine levels in serum of IBD-patients treated with vedolizumab. In this pilot study, we included 11 IBD patients (8 Crohn's disease, 3 ulcerative colitis) previously non-respondent to anti-tumor necrosis factor (TNF)-agents. Patients received vedolizumab at week 0, 2 and 6 and were evaluated for clinical efficacy at week 10...
August 22, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28815034/compliance-with-the-faecal-calprotectin-test-in-patients-with-inflammatory-bowel-disease
#15
Chloé Maréchal, Isabelle Aimone-Gastin, Cédric Baumann, Bastien Dirrenberger, Jean-Louis Guéant, Laurent Peyrin-Biroulet
BACKGROUND: We investigated, for the first time, levels of compliance with faecal calprotectin test in inflammatory bowel disease patients. METHODS: All consecutive adult inflammatory bowel disease patients having been prescribed an faecal calprotectin test between December 2014-July 2015 were included. At their next visit to the hospital, patients had to return a stool sample for the faecal calprotectin test and answer a simple questionnaire: 'Have you brought a stool sample? If not, why not? If so, did you encounter any difficulties when collecting the sample? Were you aware of faecal calprotectin before being asked to take the test?'...
August 2017: United European Gastroenterology Journal
https://www.readbyqxmd.com/read/28804488/anti-adhesion-therapies-in-inflammatory-bowel-disease-molecular-and-clinical-aspects
#16
REVIEW
Sebastian Zundler, Emily Becker, Carl Weidinger, Britta Siegmund
The number of biologicals for the therapy of immunologically mediated diseases is constantly growing. In contrast to other agents that were previously introduced in rheumatologic or dermatologic diseases and only later adopted for the treatment of inflammatory bowel diseases (IBDs), the field of IBD was ground breaking for the concept of anti-adhesion blockade. Anti-adhesion antibodies selectively target integrins controlling cell homing to the intestine, which leads to reduction of inflammatory infiltration to the gut in chronic intestinal inflammation...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28765121/novel-therapies-for-immune-mediated-inflammatory-diseases-what-can-we-learn-from-their-use-in-rheumatoid-arthritis-spondyloarthritis-systemic-lupus-erythematosus-psoriasis-crohn-s-disease-and-ulcerative-colitis
#17
REVIEW
Kenneth F Baker, John D Isaacs
The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and inflammatory response, fuelled by advances in both biotechnology and disease knowledge. As well as providing superior treatments for immune-mediated inflammatory diseases (IMIDs), such therapies also offer unrivalled opportunities to study the underlying immunopathological basis of these conditions.In this review, we explore recent approaches to the treatment of IMIDs and the insights to pathobiology that they provide...
August 1, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28724302/efficacy-and-safety-of-vedolizumab-as-a-treatment-option-for-moderate-to-severe-refractory-ulcerative-colitis-in-two-patients-after-liver-transplant-due-to-primary-sclerosing-cholangitis
#18
Raúl Vicente Olmedo Martín, Víctor Amo Trillo, Rocío González Grande, Miguel Jiménez Pérez
Vedolizumab is a humanized IgG1 monoclonal antibody that selectively blocks the lymphocyte integrin α4β7 and prevents its interaction with endothelial adhesion molecules and subsequent transmigration to the gastrointestinal tract. The drug was approved in 2014 for the induction and maintenance treatment of ulcerative colitis and moderate to severe Crohn's disease that is refractory or intolerant to conventional treatment with corticoids and immunosuppressants and/or anti-TNFα drugs. However, inflammatory bowel disease has a variable behavior following liver transplant...
September 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28719595/risk-of-postoperative-complications-among-inflammatory-bowel-disease-patients-treated-preoperatively-with-vedolizumab
#19
Akihiro Yamada, Yuga Komaki, Nayan Patel, Fukiko Komaki, Arthur S Aelvoet, Anthony L Tran, Joel Pekow, Sushila Dalal, Russell D Cohen, Lisa Cannon, Konstantin Umanskiy, Radhika Smith, Roger Hurst, Neil Hyman, David T Rubin, Atsushi Sakuraba
OBJECTIVES: Vedolizumab is increasingly used to treat patients with ulcerative colitis (UC) and Crohn's disease (CD), however, its safety during the perioperative period remains unclear. We compared the 30-day postoperative complications among patients treated preoperatively with vedolizumab, anti-tumor necrosis factor (TNF)-α agents or non-biological therapy. METHODS: The retrospective study cohort was comprised of patients receiving vedolizumab, anti-TNF-α agents or non-biological therapy within 4 weeks of surgery...
September 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28717358/clinical-response-to-vedolizumab-in-ulcerative-colitis-patients-is-associated-with-changes-in-integrin-expression-profiles
#20
Friederike Fuchs, Daniela Schillinger, Raja Atreya, Simon Hirschmann, Sarah Fischer, Clemens Neufert, Imke Atreya, Markus F Neurath, Sebastian Zundler
BACKGROUND: Despite large clinical success, deeper insights into the immunological effects of vedolizumab therapy for inflammatory bowel diseases are scarce. In particular, the reasons for differential clinical response in individual patients, the precise impact on the equilibrium of integrin-expressing T cell subsets, and possible associations between these issues are not clear. METHODS: Blood samples from patients receiving clinical vedolizumab therapy were sequentially collected and analyzed for expression of integrins and chemokine receptors on T cells...
2017: Frontiers in Immunology
keyword
keyword
45192
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"